These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 16395411

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.
    van Wijngaarden P, Qureshi SH.
    Clin Exp Optom; 2008 Sep; 91(5):427-37. PubMed ID: 18637105
    [Abstract] [Full Text] [Related]

  • 3. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
    Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I.
    Drugs Aging; 2007 Sep; 24(8):643-62. PubMed ID: 17702534
    [Abstract] [Full Text] [Related]

  • 4. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.
    Ng EW, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP.
    Nat Rev Drug Discov; 2006 Feb; 5(2):123-32. PubMed ID: 16518379
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of neovascular age-related macular degeneration with antiangiogenic drugs].
    Rodrigues EB, Rossi EE, Grumann Junior A, Meyer CH, Ho AC.
    Arq Bras Oftalmol; 2006 Feb; 69(5):756-65. PubMed ID: 17187150
    [Abstract] [Full Text] [Related]

  • 6. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
    Takeda AL, Colquitt J, Clegg AJ, Jones J.
    Br J Ophthalmol; 2007 Sep; 91(9):1177-82. PubMed ID: 17475698
    [Abstract] [Full Text] [Related]

  • 7. New treatments for age-related macular degeneration.
    Imrie FR, Bailey C.
    Age Ageing; 2007 Jan; 36(1):8-10. PubMed ID: 17264135
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antivascular endothelial growth factors in age-related macular degeneration.
    Schmidt-Erfurth U, Pollreisz A, Mitsch C, Bolz M.
    Dev Ophthalmol; 2010 Jan; 46():21-38. PubMed ID: 20703030
    [Abstract] [Full Text] [Related]

  • 10. Pegaptanib for neovascular age-related macular degeneration.
    Maberley D.
    Issues Emerg Health Technol; 2005 Dec; (76):1-4. PubMed ID: 16544440
    [Abstract] [Full Text] [Related]

  • 11. [New drugs; pegaptanib and ranibizumab].
    van Bronswijk H, Dubois EA, van Meurs JC, Cohen AF.
    Ned Tijdschr Geneeskd; 2008 Jan 12; 152(2):82-4. PubMed ID: 18265796
    [Abstract] [Full Text] [Related]

  • 12. Pegaptanib in the treatment of wet, age-related macular degeneration.
    Vinores SA.
    Int J Nanomedicine; 2006 Jan 12; 1(3):263-8. PubMed ID: 17717967
    [Abstract] [Full Text] [Related]

  • 13. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.
    Vedula SS, Krzystolik MG.
    Cochrane Database Syst Rev; 2008 Apr 16; (2):CD005139. PubMed ID: 18425911
    [Abstract] [Full Text] [Related]

  • 14. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.
    Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, Recchia FM, American Academy of Ophthalmology.
    Ophthalmology; 2008 Oct 16; 115(10):1837-46. PubMed ID: 18929163
    [Abstract] [Full Text] [Related]

  • 15. Pegaptanib for the treatment of age-related macular degeneration.
    Zhou B, Wang B.
    Exp Eye Res; 2006 Sep 16; 83(3):615-9. PubMed ID: 16678158
    [Abstract] [Full Text] [Related]

  • 16. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
    Macugen AMD Study GroupDepartment of Ophthalmology and Visual Sciences, Washington University in St. Louis School of Medicine, St. Louis, Missouri 63110, USA., Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP.
    Ophthalmology; 2007 Sep 16; 114(9):1702-12. PubMed ID: 17509689
    [Abstract] [Full Text] [Related]

  • 17. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.
    Tolentino M.
    Surv Ophthalmol; 2011 Sep 16; 56(2):95-113. PubMed ID: 21335144
    [Abstract] [Full Text] [Related]

  • 18. Regulatory aspects of drug approval for macular degeneration.
    Gryziewicz L.
    Adv Drug Deliv Rev; 2005 Dec 13; 57(14):2092-8. PubMed ID: 16316706
    [Abstract] [Full Text] [Related]

  • 19. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.
    Quiram PA, Hassan TS, Williams GA.
    Retina; 2007 Sep 13; 27(7):851-6. PubMed ID: 17891008
    [Abstract] [Full Text] [Related]

  • 20. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
    Ng EW, Adamis AP.
    Can J Ophthalmol; 2005 Jun 13; 40(3):352-68. PubMed ID: 15947805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.